140 related articles for article (PubMed ID: 16696803)
1. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Jun; 23(11):1559-66. PubMed ID: 16696803
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients.
Fabrizi F; Dixit V; Messa P; Martin P
Aliment Pharmacol Ther; 2010 Sep; 32(6):756-62. PubMed ID: 20662784
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease.
Fabrizi F; Ganeshan SV; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(5):789-96. PubMed ID: 16918882
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.
Alavian SM; Tabatabaei SV
Clin Ther; 2010 Jan; 32(1):1-10. PubMed ID: 20171406
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease.
Fabrizi F; Martin P; Dixit V; Bunnapradist S; Dulai G
Aliment Pharmacol Ther; 2004 Nov; 20(10):1053-62. PubMed ID: 15569107
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population.
Fabrizi F; Dixit V; Bunnapradist S; Martin P
Aliment Pharmacol Ther; 2006 Apr; 23(8):1105-12. PubMed ID: 16611270
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: meta-analysis of clinical studies.
Fabrizi F; Dixit V; Martin P; Messa P
J Viral Hepat; 2011 Dec; 18(12):871-6. PubMed ID: 22093033
[TBL] [Abstract][Full Text] [Related]
9. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature.
Alavian SM; Tabatabaei SV
Vaccine; 2010 May; 28(22):3773-7. PubMed ID: 20371390
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed.
Prescrire Int; 2008 Dec; 17(98):234-6. PubMed ID: 19422145
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients.
Fabrizi F; Dixit V; Martin P; Messa P
Aliment Pharmacol Ther; 2011 Apr; 33(7):815-21. PubMed ID: 21281319
[TBL] [Abstract][Full Text] [Related]
12. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
J Viral Hepat; 2011 Oct; 18(10):730-7. PubMed ID: 20819147
[TBL] [Abstract][Full Text] [Related]
13. Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination.
Dumann H; Meuer SC; Renschin G; Köhler H
Nephron; 1990; 55(2):136-40. PubMed ID: 2194133
[TBL] [Abstract][Full Text] [Related]
14. The role of thymopentin in hemodialyzed hepatitis B vaccine non-responders.
Peralta S; Ribisi La Spina AM; Genovese G; La Iuppa M; Rotolo G; Tumbiolo S; Rini GB; Colimberti D
J Chemother; 1989 Jul; 1(4 Suppl):1084-5. PubMed ID: 16312782
[No Abstract] [Full Text] [Related]
15. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies.
Grob PJ; Binswanger U; Blumberg A; Gloor HJ; Hany A; Herwig W; Iselin H; Zàruba K; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():107-15. PubMed ID: 3898281
[TBL] [Abstract][Full Text] [Related]
16. [Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: controlled study in patients on periodic hemodialysis].
Palestini M; Messina A; Ciaraffo F; De Sanctis GM; Errera G; Corradini SG
Riv Eur Sci Med Farmacol; 1990 Apr; 12(2):135-9. PubMed ID: 2080311
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis.
Fabrizi F; Dixit V; Martin P; Messa P
Kidney Blood Press Res; 2012; 35(6):504-10. PubMed ID: 22813903
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus vaccine in chronic kidney diseases: improved immunogenicity by adjuvants? Limits of a meta-analysis.
Di Pasquale A; De Ridder M; Van Der Meeren O
Vaccine; 2012 Aug; 30(38):5586. PubMed ID: 22749597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
